We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 8,720

Savvy food companies beef up their IP protection for vegan products
  • Barker Brettell LLP
  • United Kingdom
  • August 17 2017

There’s a veggie-driven revolution going on in the food industry right now. Led by customer demand for meat alternatives (the number of vegans in


Post-Grant Amendments from Method of Treatment to Swiss-Style - The Singapore Position
  • Mirandah Asia
  • Singapore
  • August 17 2017

In the landmark case of Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd 2017 SGCA 45, the Singapore Court of Appeal explored, inte


The Impact of Biosimilars on Global Pharmaceutical Markets
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 17 2017

Biologic drugs are quickly reshaping the pharmaceutical landscape as they dominate the drug market in annual sales revenue. AbbVie’s Humira


Biosimilars in the US: the next frontier for big pharma
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 17 2017

The market for biological drug products is forecast to reach a global value of $400bn per year by 2025. Major pharmaceutical companies are investing


You snooze you lose!
  • S Horowitz & Co
  • Israel
  • August 17 2017

Interested in Patent Term Extensions for medical device in Israel? Be ready for prompt action


AbbVie Files BPCIA Suit Against Boehringer Ingelheim Over Humira (Adalimumab)
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 16 2017

Recently, AbbVie, Inc. and AbbVie Biotechnology, LTD (collectively “AbbVie” or “Plaintiffs”) filed a Complaint in the United States District Court


Pharmaceutical IP and competition law in Mexico: overview
  • OLIVARES
  • Mexico
  • August 16 2017

What are the legal conditions to obtain a patent and which legislation applies? Which products, substances and processes can be protected by patents


Considerations for Developing a Global Patent Term Extension Strategy
  • Sterne Kessler Goldstein & Fox PLLC
  • Global
  • August 15 2017

Many jurisdictions provide for the extension of the term of the patents that cover a regulated product. Patent term extension (PTE) is particularly


Patent Term Extension Considerations for BioPharma Patents
  • Sterne Kessler Goldstein & Fox PLLC
  • USA
  • August 15 2017

Time spent on securing marketing approval for regulated products, such as pharmaceuticals, medical devices and agrochemicals effectively shortens the


Insufficient disclosure in biotechnology
  • WAN HUI DA
  • China
  • August 14 2017

In Re-examination Decision 68977 (1F137820), the Patent Re-examination Board overturned a rejection that was based on insufficient disclosure. The